BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Feb 08, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Tapentadol ER: Phase III data

Data from a Phase III trial in 395 patients showed that 100-250 mg twice-daily tapentadol ER significantly reduced average pain intensity from baseline to week 12 of the double-blind maintenance period vs. placebo (p<0.001). Specifically, tapentadol ER reduced average pain intensity by 0.1 points from baseline to week 12 of the maintenance period vs. a 1.3 point increase for...

Read the full 274 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >